6-SUBSTITUTED PROSTAGLANDIN E1'S AND PROCESS FOR THEIR PREPARATION

摘要

PCT No. PCT/JP85/00096 Sec. 371 Date Oct. 18, 1985 Sec. 102(e) Date Oct. 18, 1985 PCT Filed Feb. 28, 1985 PCT Pub. No. WO85/03935 PCT Pub. Date Sep. 12, 1985.6-substituted prostaglandins E1 which are compounds represented by the following formula [I] or their enantiomers or mixtures whereof in any ratio: [I] wherein R1 represents a hydrogen atom, a C1-C16 alkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted phenyl C3-C10 cycloalkyl group, a substituted or unsubstituted phenyl (C1-C2) alkyl group, or one equivalent cation; R2 and R3, which may be the same or different, represent a hydrogen atom, a tri (C1-C7) hydrocarbon silyl group, or a group forming an acetal linkage together with an oxygen atom of a hydroxyl group; R4 represents a hydrogen atom, a methyl group or a vinyl group; R5 represents a linear or branched C3-C8 alkyl group, a linear or branched C3-C8 alkenyl group, a linear or branced C3-C8 alkynyl group, a phenyl group which may be substituted, a phenoxy group which may be substituted, a C3-C10 cycloalkyl group which may be substituted, or a linear or branched C1-C5 alkyl group which may be substituted with a C1-C6 alkoxy group, a phenyl group which may be substituted, a phenoxy group which may be substituted, or a C3-C10 cycloalkyl group which may be substituted; and X represents an group or an oxygen atom. Such 6-substituted prostaglandins E1 are useful for the treatment and/or prevention of digestive organ diseases such as duodenal ulcers or gastric ulcers.